Acetylsalicylic acid/dipyridamole
| |
Combination of | |
---|---|
Acetylsalicylic acid | Antithrombotic |
Dipyridamole | Antithrombotic |
Clinical data | |
Trade names | Aggrenox, Asasantin |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | Oral |
ATC code | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider |
The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]
- Acetylsalicylic acid, the analgesic otherwise (but in higher doses) trademarked as Aspirin
- Dipyridamole, a drug that inhibits thrombus formation[2] when given chronically and causes vasodilation when given at high doses over short time.
The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events and stroke.[3] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[4]
References
- ↑ FASS (the Swedish official drug catalog) > Asasantin Last update: 2009–08–17
- ↑ "Dipyridamole" at Dorland's Medical Dictionary
- ↑ Malinin, Alex I.; Eisert, Roswith M.; Atar, Dan; Barkagan, Zinoviy; Serebruany, Victor L. (2002). "Aggrenox® (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events". Heart Drug. 2 (2): 93–104. doi:10.1159/000063427.
- ↑ Serebruany, Victor L.; Malinin, Alex I.; Sane, David C.; Jilma, Bernd; Takserman, Aviv; Atar, Dan; Hennekens, Charles H. (September 2004). "Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial". European Journal of Pharmacology. 499 (3): 315–324. doi:10.1016/j.ejphar.2004.07.114. PMID 15381054.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.